In cancer therapy, physicians need to assess huge amounts of complex medical data. KAIT is a digital platform which uses extensive data analysis to evaluate this information so doctors can identify the best treatment option for each individual patient.
This R&D initiative from Leipzig has a clear vision: To make patient care in oncology and beyond more personalized and effective. KAIT provides a virtual simulation of multiple treatment options, enabling a data-driven prognosis of therapeutic success factors to help doctors identify an optimal strategy.
Why it has to be Leipzig
KAIT’s genesis as an innovative R&D initiative can be traced back to a unique combination of forward-looking institutions and specialized know-how which can only be found in Leipzig:
The Innovation Center Computer Assisted Surgery (ICCAS), which is a pioneer for computer-aided assistance systems in medicine, helped launch KAIT.
The initiative was also initiated by the Clinic for Hematology, Cell Therapy and Hemostaseology at Leipzig University Hospital, which has a specialized profile in state-of-the-art cancer treatment.
Renowned pharmaceutical manufacturer Janssen Germany (Johnson & Johnson) became a corporate partner.
These productive cross-sector collaborations and the ‘can-do’ attitude which Leipzig is known for not only proved to be a perfect launch pad for KAIT. Leipzig also continues to provide optimal conditions for the initiative’s medical and IT specialists to connect both worlds.
“The integration of intelligent software systems such as KAIT is a crucial and necessary step to help physicians deal with the emerging complexity of information along a patient’s therapeutic path,”
says KAIT project lead Prof. Dr. Thomas Neumuth. “With KAIT, we are able to effectively connect best-in-class clinical and data science expertise to generate valuable insights that will facilitate both patient care and clinical research,” says technical project lead Dr. Alexander Oeser.
That is lifechanging
KAIT is shaping the future of clinical decision-making: Physicians know they can rely on its technologies to find the best treatment options, and thus patients can trust that they will receive a therapy which is personalized to meet their specific needs.
Founded in 2019, KAIT is a collaborative R&D venture between ICCAS, Leipzig University Hospital, Merantix Momentum and Janssen Germany. Its team of medical and IT experts is based at the University Medical Center Leipzig. Although its solutions are currently adapted to the field of hematology, KAIT plans to extend them to include other clinical disciplines in the near future. Find out more at kait.health
A relatively small metropolis in Germany’s Free State of Saxony – a dynamic hub for the life science industry? What was just a vision 20 years ago has become a reality for the city of Leipzig, which from October 24-26 co-hosted BIO-Europe, Europe’s largest annual biotech partnering event.
Innovative gene and cell therapies have the potential to treat previously incurable serious diseases. SaxoCell® is bringing strong German players from this field together to develop and produce these ‘living drugs’ for safe, effective and affordable treatment.